BML Capital Management, LLC - Q2 2023 holdings

$111 Million is the total value of BML Capital Management, LLC's 31 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 0.0% .

 Value Shares↓ Weighting
BIL  SPDR SER TRbloomberg 1-3 mo$18,364,0000.0%200,0000.0%16.52%
+4.1%
ATHA  ATHIRA PHARMA INC$5,501,476
+18.0%
1,864,9070.0%4.95%
+22.8%
 ASTROTECH CORP$3,121,006
+32.8%
220,4100.0%2.81%
+38.2%
FBRX  FORTE BIOSCIENCES INC$1,804,478
+3.0%
1,735,0750.0%1.62%
+7.1%
ABIO  ARCA BIOPHARMA INC$1,435,068
+2.0%
706,9300.0%1.29%
+6.2%
 LISATA THERAPEUTICS INC$902,204
+14.0%
243,8390.0%0.81%
+18.7%
VRCA  VERRICA PHARMACEUTICALS INC$865,500
-11.2%
150,0000.0%0.78%
-7.6%
RVP  RETRACTABLE TECHNOLOGIES INC$768,861
-34.3%
668,5750.0%0.69%
-31.6%
NXTC  NEXTCURE INC$551,637
+21.6%
306,4650.0%0.50%
+26.5%
GRPH  GRAPHITE BIO INC$395,957
+6.1%
152,2910.0%0.36%
+10.2%
NLTX  NEOLEUKIN THERAPEUTICS INC$19,712
+18.6%
23,7490.0%0.02%
+28.6%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-07-24
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
SPDR SER TR7Q2 202416.9%
ATHIRA PHARMA INC7Q2 20244.9%
ASTROTECH CORP7Q2 20242.8%
FORTE BIOSCIENCES INC7Q2 20241.6%
VERRICA PHARMACEUTICALS INC7Q2 20242.9%
MILESTONE PHARMACEUTICALS IN7Q2 20241.0%
LISATA THERAPEUTICS INC7Q2 20240.8%
ISHARES TR6Q2 202425.0%
ELIEM THERAPEUTICS INC6Q1 20246.4%
ORAMED PHARMACEUTICALS INC6Q2 20242.7%

View BML Capital Management, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-08-07
N-PX2024-08-07
13F-HR/A2024-04-24
13F-HR2024-04-23
13F-HR/A2024-02-02
13F-HR2024-01-30
13F-HR2023-10-23
13F-HR2023-07-24
13F-HR2023-04-14
13F-HR2023-02-13

View BML Capital Management, LLC's complete filings history.

Export BML Capital Management, LLC's holdings